SCHEMBL5651257

SCHEMBL5651257

CCOC(=O)c1sc2c(ccc(=O)n2C(C(=O)OCc2ccccc2)C2CCNCC2)c1-c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NMT1 P30419 2/20 0.40
PLAT P00750 2/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
ACACB O00763 1/20 0.35
ACACA Q13085 1/20 0.35
CDC7 O00311 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
DBF4 Q9UBU7 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.34
ROCK2 O75116 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPK1 P28482 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
PPARG P37231 1/20 0.34
ELANE P08246 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650265 0.84 PLAT (0.37) PLATKMT2AMEN1CDC7TRPM8
SCHEMBL5651276 0.78 PLAT (0.40) PLATKMT2AMEN1CDC7TRPM8
SCHEMBL5650255 0.75 HPGD (0.43) KMT2AMEN1CDC7TRPM8DBF4
SCHEMBL5651246 0.73 SMN1; SMN2 (0.42) KMT2AMEN1ALDH1A1NPC1RAB9A
SCHEMBL5651454 0.73 ALDH1A1 (0.54) KMT2AMEN1ACACBACACACDC7
SCHEMBL5651283 0.73 MAPK8 (0.40) KMT2AMEN1CDC7TRPM8DBF4
SCHEMBL5652931 0.71 ACACB (0.53) KMT2AMEN1ACACBACACACDC7
SCHEMBL5650904 0.71 PPARG (0.46) KMT2AMEN1CDC7TRPM8DBF4
SCHEMBL5650136 0.71 MAPT (0.51) KMT2AMEN1CDC7TRPM8DBF4
SCHEMBL5647564 0.70 MAPK8 (0.47) KMT2AMEN1CDC7TRPM8DBF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 NMT1 2144/4885PLAT 4042/4885KMT2A 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.